Surmodics, Inc. (NASDAQ:SRDX) Files An 8-K Submission of Matters to a Vote of Security Holders
Item 5.07 Submission of Matters to a Vote of Security Holders.
On February 14, 2017, the Company held its 2017 Annual Meeting of
Shareholders. The final voting results of the proposals which
were described in more detail in the Companys proxy statement
filed with the Securities and Exchange Commission on December 22,
2016, are set forth below.
1. Election of Directors. Each of the individuals
nominated by the Companys Board of Directors to serve as Class II
directors was duly elected by the Companys shareholders, and the
final results of the votes cast are as follows:
| For | Withheld | Broker Non-Votes | |
| Jos H. Bedoya | 10,500,212 | 241,706 | 1,325,383 |
| Susan E. Knight | 10,529,735 | 212,183 | 1,325,383 |
2. Set the Number of Directors. The Companys shareholders
approved the proposal to set the number of directors at six (6)
by the following vote:
| For | Against | Abstain | Broker Non-Votes |
| 11,902,468 | 103,177 | 41,052 | – |
3. Ratification of the Appointment of Deloitte Touche LLP.
The Companys shareholders ratified the appointment of Deloitte
Touche LLP as the Companys independent registered public
accounting firm for fiscal year 2017 by the following vote:
| For | Against | Abstain | Broker Non-Votes |
| 11,989,328 | 50,093 | 7,276 | – |
4. Advisory Vote on Executive Compensation. The Companys
shareholders approved the compensation of the Companys named
executive officers, on an advisory basis, by the following vote:
| For | Against | Abstain | Broker Non-Votes |
| 10,335,759 | 370,846 | 14,709 | 1,325,383 |
5. Frequency of Advisory Vote on Executive Compensation.
The Companys shareholders approved, on an advisory basis, the
proposal recommending that the advisory vote on executive
compensation should occur on an annual basis. The final voting
results for this proposal were as follows:
| One Year | Two Years | Three Years | Abstain |
| 8,986,709 | 45,544 | 1,674,697 | 14,364 |
About Surmodics, Inc. (NASDAQ:SRDX)
Surmodics, Inc. is a provider of medical device and in vitro diagnostic technologies to the healthcare industry. The Company operates through two segments: Medical Device and In Vitro Diagnostics. The Company’s Medical Device segment consists of surface modification coating technologies to improve access, deliverability and predictable deployment of medical devices; international cardiology and peripheral balloon design, development and manufacturing, as well as drug delivery coating technologies to provide site-specific drug delivery from the surface of a medical device. The Company’s In Vitro Diagnostics segment manufactures or sells components for in vitro diagnostic immunoassay and molecular tests. The In Vitro Diagnostics segment manufactures and sells surface coatings to the diagnostic, biomedical research and life science markets. In Vitro Diagnostics segment offers protein stabilization reagents, substrates, antigens and surface coatings. Surmodics, Inc. (NASDAQ:SRDX) Recent Trading Information
Surmodics, Inc. (NASDAQ:SRDX) closed its last trading session up +0.35 at 24.80 with 27,663 shares trading hands.
